About
Dogma Therapeutics discovers and develops orally bioavailable small molecule inhibitors targeting PCSK9 to reduce cholesterol and treat cardiovascular disease.
Explore Dogma Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.